ナノボディの市場規模は、2022 年から 2030 年までの予測期間中に 24.2% の CAGR で 2030 年までに 11億4,000万ドルに達すると予測されます。
ナノボディは、哺乳動物の重鎖抗体に由来する単一ドメイン抗体であり、ナノサイズ、堅牢な構造、水溶液中での安定性と可溶性の挙動、可逆的なタンパク質リフォールディングなどの独自の特性を備えています。ナノボディは親和性が高く、その親水性領域によりオフターゲットの蓄積が少ない抗原を特異的にターゲットにすることができます。また、高温高圧、化学変性剤、非生理的 pH にも耐えることができます。
ナノボディの市場は、がんやその他の慢性疾患の有病率の増加、R&D 活動の増加、などの要因によって、予測期間中に大幅に上昇すると予想され、ナノボディ製品の臨床試験の成功とその後の承認がナノボディ市場の成長を後押しするでしょう。たとえば、2019 年 2 月、FDAは、後天性血栓性血小板減少性紫斑病 (aTTP) の成人向けの最初のナノボディベースの医薬品である Cablivi (caplacizumab-yhdp) を承認しました。さらに、主要なプレーヤーや国立衛生研究所 (NIH) などのさまざまな政府の医学研究機関は、治療用ナノボディの進歩のための研究開発活動に熱心に取り組んでいます。これはまた、予測期間中に世界のナノボディ市場の成長を促進すると予想されます。たとえば、2020 年 12 月 21 日にネイチャー ジャーナルに掲載された記事によると、国立衛生研究所の研究者は、SARS-CoV-2 に対して一連のナノボディを分離しました。このナノボディは NIH-CoVnb-112 と呼ばれ、SARS-Cov-2 スパイクタンパク質のバリアント型に結合してブロックします。
目次
TABLE OF CONTENTS
1. EXECUTIVE SUMMARY
2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the Study
2.2.1. Research Objective
2.2.2. Assumptions
2.2.3. Limitations
3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Data Mining
3.3. Secondary Research
3.4. Primary Research
3.4.1. Primary Interviews and Information Gathering Process
3.4.2. Breakdown of Primary Respondents
3.5. Forecasting Techniques
3.6. Market Size Estimation
3.6.1. Bottom-Up Approach
3.6.2. Top-Down Approach
3.7. Data Triangulation
3.8. Validation
4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities
5. MARKET FACTOR ANALYSIS
5.1. Value Chain Analysis
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining Power of Suppliers
5.2.2. Bargaining Power of Buyers
5.2.3. Threat of New Entrants
5.2.4. Threat of Substitutes
5.2.5. Intensity of Rivalry
5.3. COVID-19 Impact Analysis
5.3.1. Market Impact Analysis
5.3.2. Impact on Supply Chain
5.3.3. Regional Impact
5.3.4. Opportunity and Threat Analysis
6. GLOBAL NANOBODY MARKET, BY TYPE
6.1. Overview
6.2. Mono-specific
6.3. Multi-specific
7. GLOBAL NANOBODY MARKET, BY APPLICATION
7.1. Overview
7.2. Therapeutic
7.2.1. Cancer
7.2.2. Neurodegenerative Diseases
7.2.3. Infectious Diseases
7.2.4. Others
7.3. Diagnostic
7.3.1. Detection of Proteins and Microorganisms
7.3.2. Detection of Small Molecules
7.3.3. Imaging
7.4. Research
8. GLOBAL NANOBODY MARKET, BY END USER
8.1. Overview
8.2. Pharmaceutical & Biotechnology Companies
8.3. Research Laboratories
8.4. Others
9. GLOBAL NANOBODY MARKET, BY REGION
9.1. Overview
9.2. North America
9.2.1. US
9.2.2. Canada
9.3. Europe
9.3.1. Germany
9.3.2. France
9.3.3. Italy
9.3.4. Spain
9.3.5. UK
9.3.6. Rest of Europe
9.4. Asia-Pacific
9.4.1. Japan
9.4.2. China
9.4.3. India
9.4.4. Australia
9.4.5. South Korea
9.4.6. Rest of Asia-Pacific
9.5. Rest of the World
9.5.1. Middle East
9.5.2. Africa
9.5.3. Latin America
10. COMPANY LANDSCAPE
10.1. Overview
10.2. Competitive Analysis
10.3. Market Share Analysis
10.4. Major Growth Strategy in the Global Nanobody Market
10.5. Competitive Benchmarking
10.6. Leading Players in terms of Number of Developments in the Global Nanobody Market
10.7. Key Developments and Growth Strategies
10.7.1. New Product Launch/Service Deployment
10.7.2. Merger & Acquisitions
10.7.3. Joint Ventures
10.8. Major Players Financial Matrix
10.8.1. Sales & Operating Income, 2021
10.8.2. Major Players R&D Expenditure, 2021
11. COMPANY PROFILES
11.1. Sanofi S.A.
11.1.1. Company Overview
11.1.2. Key Financials
11.1.3. Products Offered
11.1.4. Key Developments
11.1.5. SWOT Analysis
11.1.6. Key Strategies
11.2. Merck KGaA
11.2.1. Company Overview
11.2.2. Key Financials
11.2.3. Products Offered
11.2.4. Key Developments
11.2.5. SWOT Analysis
11.2.6. Key Strategies
11.3. Alphamab Oncology
11.3.1. Company Overview
11.3.2. Key Financials
11.3.3. Products Offered
11.3.4. Key Developments
11.3.5. SWOT Analysis
11.3.6. Key Strategies
11.4. Bristol Myers Squibb
11.4.1. Company Overview
11.4.2. Key Financials
11.4.3. Products Offered
11.4.4. Key Developments
11.4.5. SWOT Analysis
11.4.6. Key Strategies
11.5. Novartis AG
11.5.1. Company Overview
11.5.2. Key Financials
11.5.3. Products Offered
11.5.4. Key Developments
11.5.5. SWOT Analysis
11.5.6. Key Strategies
11.6. GenScript Biotech Corporation
11.6.1. Company Overview
11.6.2. Key Financials
11.6.3. Products Offered
11.6.4. Key Developments
11.6.5. SWOT Analysis
11.6.6. Key Strategies
11.7. Sensei Biotherapeutics
11.7.1. Company Overview
11.7.2. Key Financials
11.7.3. Products Offered
11.7.4. Key Developments
11.7.5. SWOT Analysis
11.7.6. Key Strategies
11.8. Beroni Group
11.8.1. Company Overview
11.8.2. Key Financials
11.8.3. Products Offered
11.8.4. Key Developments
11.8.5. SWOT Analysis
11.8.6. Key Strategies
11.9. DiosCURE Therapeutics SE
11.9.1. Company Overview
11.9.2. Key Financials
11.9.3. Products Offered
11.9.4. Key Developments
11.9.5. SWOT Analysis
11.9.6. Key Strategies
11.10. ExeVir Bio BV
11.10.1. Company Overview
11.10.2. Key Financials
11.10.3. Products Offered
11.10.4. Key Developments
11.10.5. SWOT Analysis
11.10.6. Key Strategies
11.11. Taisho Pharmaceutical Holdings Co., Ltd.
11.11.1. Company Overview
11.11.2. Key Financials
11.11.3. Products Offered
11.11.4. Key Developments
11.11.5. SWOT Analysis
11.11.6. Key Strategies
12. APPENDIX
12.1. References
12.2. Related Reports
?
LIST OF TABLES
TABLE 1 GLOBAL NANOBODY MARKET SYNOPSIS, 2018-2030
TABLE 2GLOBAL NANOBODY MARKET ESTIMATES & FORECAST, 2018-2030 (USD MILLION)
TABLE 3 GLOBAL NANOBODY MARKET, BY TYPE, 2018-2030 (USD MILLION)
TABLE 4 GLOBAL NANOBODY MARKET, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 5 GLOBAL NANOBODY MARKET, BY END USER, 2018-2030 (USD MILLION)
TABLE 6 NORTH AMERICA: NANOBODY MARKET, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 7 NORTH AMERICA: NANOBODY MARKET, BY TYPE, 2018-2030 (USD MILLION)
TABLE 8 NORTH AMERICA: NANOBODY MARKET, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 9 NORTH AMERICA: NANOBODY MARKET, BY END USER, 2018-2030 (USD MILLION)
TABLE 10 US: NANOBODY MARKET, BY TYPE, 2018-2030 (USD MILLION)
TABLE 11 US: NANOBODY MARKET, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 12 US: NANOBODY MARKET, BY END USER, 2018-2030 (USD MILLION)
TABLE 13 CANADA: NANOBODY MARKET, BY TYPE, 2018-2030 (USD MILLION)
TABLE 14 CANADA: NANOBODY MARKET, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 15 CANADA: NANOBODY MARKET, BY END USER, 2018-2030 (USD MILLION)
TABLE 16 EUROPE: NANOBODY MARKET, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 17 EUROPE: NANOBODY MARKET, BY TYPE, 2018-2030 (USD MILLION)
TABLE 18 EUROPE: NANOBODY MARKET, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 19 EUROPE: NANOBODY MARKET, BY END USER, 2018-2030 (USD MILLION)
TABLE 20 GERMANY: NANOBODY MARKET, BY TYPE, 2018-2030 (USD MILLION)
TABLE 21 GERMANY: NANOBODY MARKET, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 22 GERMANY: NANOBODY MARKET, BY END USER, 2018-2030 (USD MILLION)
TABLE 23 FRANCE: NANOBODY MARKET, BY TYPE, 2018-2030 (USD MILLION)
TABLE 24 FRANCE: NANOBODY MARKET, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 25 FRANCE: NANOBODY MARKET, BY END USER, 2018-2030 (USD MILLION)
TABLE 26 ITALY: NANOBODY MARKET, BY TYPE, 2018-2030 (USD MILLION)
TABLE 27 ITALY: NANOBODY MARKET, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 28 ITALY: NANOBODY MARKET, BY END USER, 2018-2030 (USD MILLION)
TABLE 29 SPAIN: NANOBODY MARKET, BY TYPE, 2018-2030 (USD MILLION)
TABLE 30 SPAIN: NANOBODY MARKET, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 31 SPAIN: NANOBODY MARKET, BY END USER, 2018-2030 (USD MILLION)
TABLE 32 UK: NANOBODY MARKET, BY TYPE, 2018-2030 (USD MILLION)
TABLE 33 UK: NANOBODY MARKET, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 34 UK: NANOBODY MARKET, BY END USER, 2018-2030 (USD MILLION)
TABLE 35 REST OF EUROPE: NANOBODY MARKET, BY TYPE, 2018-2030 (USD MILLION)
TABLE 36 REST OF EUROPE: NANOBODY MARKET, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 37 REST OF EUROPE: NANOBODY MARKET, BY END USER, 2018-2030 (USD MILLION)
TABLE 38 ASIA-PACIFIC: NANOBODY MARKET, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 39 ASIA-PACIFIC: NANOBODY MARKET, BY TYPE, 2018-2030 (USD MILLION)
TABLE 40 ASIA-PACIFIC: NANOBODY MARKET, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 41 ASIA-PACIFIC: NANOBODY MARKET, BY END USER, 2018-2030 (USD MILLION)
TABLE 42 JAPAN: NANOBODY MARKET, BY TYPE, 2018-2030 (USD MILLION)
TABLE 43 JAPAN: NANOBODY MARKET, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 44 JAPAN: NANOBODY MARKET, BY END USER, 2018-2030 (USD MILLION)
TABLE 45 CHINA: NANOBODY MARKET, BY TYPE, 2018-2030 (USD MILLION)
TABLE 46 CHINA: NANOBODY MARKET, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 47 CHINA: NANOBODY MARKET, BY END USER, 2018-2030 (USD MILLION)
TABLE 48 INDIA: NANOBODY MARKET, BY TYPE, 2018-2030 (USD MILLION)
TABLE 49 INDIA: NANOBODY MARKET, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 50 INDIA: NANOBODY MARKET, BY END USER, 2018-2030 (USD MILLION)
TABLE 51 AUSTRALIA: NANOBODY MARKET, BY TYPE, 2018-2030 (USD MILLION)
TABLE 52 AUSTRALIA: NANOBODY MARKET, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 53 AUSTRALIA: NANOBODY MARKET, BY END USER, 2018-2030 (USD MILLION)
TABLE 54 SOUTH KOREA: NANOBODY MARKET, BY TYPE, 2018-2030 (USD MILLION)
TABLE 55 SOUTH KOREA: NANOBODY MARKET, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 56 SOUTH KOREA: NANOBODY MARKET, BY END USER, 2018-2030 (USD MILLION)
TABLE 57 REST OF ASIA-PACIFIC: NANOBODY MARKET, BY TYPE, 2018-2030 (USD MILLION)
TABLE 58 REST OF ASIA-PACIFIC: NANOBODY MARKET, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 59 REST OF ASIA-PACIFIC: NANOBODY MARKET, BY END USER, 2018-2030 (USD MILLION)
TABLE 60 REST OF THE WORLD: NANOBODY MARKET, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 61 REST OF THE WORLD: NANOBODY MARKET, BY TYPE, 2018-2030 (USD MILLION)
TABLE 62 REST OF THE WORLD: NANOBODY MARKET, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 63 REST OF THE WORLD: NANOBODY MARKET, BY END USER, 2018-2030 (USD MILLION)
TABLE 64 MIDDLE EAST: NANOBODY MARKET, BY TYPE, 2018-2030 (USD MILLION)
TABLE 65 MIDDLE EAST: NANOBODY MARKET, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 66 MIDDLE EAST: NANOBODY MARKET, BY END USER, 2018-2030 (USD MILLION)
TABLE 67 AFRICA: NANOBODY MARKET, BY TYPE, 2018-2030 (USD MILLION)
TABLE 68 AFRICA: NANOBODY MARKET, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 69 AFRICA: NANOBODY MARKET, BY END USER, 2018-2030 (USD MILLION)
TABLE 70 LATIN AMERICA: NANOBODY MARKET, BY TYPE, 2018-2030 (USD MILLION)
TABLE 71 LATIN AMERICA: NANOBODY MARKET, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 72 LATIN AMERICA: NANOBODY MARKET, BY END USER, 2018-2030 (USD MILLION)
LIST OF FIGURES
FIGURE 1 RESEARCH PROCESS
FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL NANOBODY MARKET
FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL NANOBODY MARKET
FIGURE 4 GLOBAL NANOBODY MARKET SHARE, BY TYPE, 2021 (%)
FIGURE 5 GLOBAL NANOBODY MARKET SHARE, BY APPLICATION, 2021 (%)
FIGURE 6 GLOBAL NANOBODY MARKET SHARE, BY END USER, 2021 (%)
FIGURE 7 GLOBAL NANOBODY MARKET SHARE, BY REGION, 2021 (%)
FIGURE 8 NORTH AMERICA: NANOBODY MARKET SHARE, BY COUNTRY, 2021 (%)
FIGURE 9 EUROPE: NANOBODY MARKET SHARE, BY COUNTRY, 2021 (%)
FIGURE 10 ASIA-PACIFIC: NANOBODY MARKET SHARE, BY COUNTRY, 2021 (%)
FIGURE 11 REST OF THE WORLD: NANOBODY MARKET SHARE, BY COUNTRY, 2021 (%)
FIGURE 12 GLOBAL NANOBODY MARKET: COMPANY SHARE ANALYSIS, 2021 (%)
FIGURE 13 SANOFI S.A.: FINANCIAL OVERVIEW
FIGURE 14 SANOFI S.A.: SWOT ANALYSIS
FIGURE 15 MERCK KGAA: FINANCIAL OVERVIEW
FIGURE 16 MERCK KGAA: SWOT ANALYSIS
FIGURE 17 ALPHAMAB ONCOLOGY: FINANCIAL OVERVIEW
FIGURE 18 ALPHAMAB ONCOLOGY: SWOT ANALYSIS
FIGURE 19 BRISTOL MYERS SQUIBB: FINANCIAL OVERVIEW
FIGURE 20 BRISTOL MYERS SQUIBB: SWOT ANALYSIS
FIGURE 21 NOVARTIS AG: FINANCIAL OVERVIEW
FIGURE 22 NOVARTIS AG: SWOT ANALYSIS
FIGURE 23 GENSCRIPT BIOTECH CORPORATION: FINANCIAL OVERVIEW
FIGURE 24 GENSCRIPT BIOTECH CORPORATION: SWOT ANALYSIS
FIGURE 25 SENSEI BIOTHERAPEUTICS: FINANCIAL OVERVIEW
FIGURE 26 SENSEI BIOTHERAPEUTICS: SWOT ANALYSIS
FIGURE 27 BERONI GROUP: FINANCIAL OVERVIEW
FIGURE 28 BERONI GROUP: SWOT ANALYSIS
FIGURE 29 DIOSCURE THERAPEUTICS SE: FINANCIAL OVERVIEW
FIGURE 30 DIOSCURE THERAPEUTICS SE: SWOT ANALYSIS
FIGURE 31 EXEVIR BIO BV: FINANCIAL OVERVIEW
FIGURE 32 EXEVIR BIO BV: SWOT ANALYSIS
FIGURE 33 TAISHO PHARMACEUTICAL HOLDINGS CO., LTD.: FINANCIAL OVERVIEW
FIGURE 34 TAISHO PHARMACEUTICAL HOLDINGS CO., LTD.: SWOT ANALYSIS
